TY  - CHAP
M1  - Book, Section
TI  - Pulmonary Balloon Valvuloplasty and Percutaneous Pulmonary Valve Implantation
A1  - Saji, Mike
A1  - Lim, D. Scott
A2  - Samady, Habib
A2  - Fearon, William F.
A2  - Yeung, Alan C.
A2  - King III, Spencer B.
PY  - 2017
T2  - Interventional Cardiology, 2e
AB  - Since  percutaneous  balloon  pulmonary  valvuloplasty  (BPV)  for  pulmonary  valve  stenosis  (PS)  was  first  successfully  performed  by  Rubio-Alverez  and  Limon-Lason1  using  a  ureteral  catheter  in  1950s,  it  has  become  the  standard  of  care  for  treatment  of  isolated  PS  over  surgical  valvotomy.2,3  In  2000,  based  on  these  experiences,  the  percutaneous  pulmonary  valve  implantation  (PPVI)  was  first  performed  by  Bonhoeffer  et  al4  in  a  patient  with  a  dysfunctional  of  right  ventricle–to–pulmonary  artery  conduit.  In  2010,  the  Melody  valve  (Medtronic,  Minneapolis,  MN)  became  commercially  available  in  the  United  States  under  a  humanitarian  device  exemption  protocol  and,  more  recently,  was  awarded  postmarket  approval  by  the  US  Food  and  Drug  Administration.  Since  then,  PPVI  has  been  performed  in  over  4500  patients  in  more  than  30  countries  worldwide.  In  this  chapter,  we  will  review  BPV  and  PPVI  with  particular  focus  on  the  indication,  technical  aspect,  clinical  outcomes,  and  potential  complications.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/19
UR  - accesscardiology.mhmedical.com/content.aspx?aid=1146603817
ER  -